Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System

RecruitingObservational study

Who can join

Ages 22 and older · All sexes

Full eligibility criteria

Patient case selection to be included in the clinical assessment will be specific to Liberant and will be made according to the following criteria:

1. Patient treated is age ≥ 22 years at the time of procedure
2. Use of Liberant in accordance with the device labeling within 72 hours of index procedure

About the study

The purpose of Case-Specific Health Care Professional (HCP) Clinical Survey of Liberant™ Thrombectomy System, also known as the Liberant Clinical Assessment, is to collect first-in-human clinical data to confirm the safety and performance of the Medtronic Liberant™ thrombectomy system when used for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems

What is being tested

Liberant Thrombectomy System (device)

Sponsor: Medtronic Endovascular · Participants: 50 · Started: Feb 24, 2026

Contact the study team

Manasa Gudipally · Phone: 763-514-4000

Official record on ClinicalTrials.gov — NCT07335341

Locations in the U.S.

District of Columbia	MedStar Health, Washington D.C.
Florida	Naples Comprehensive Health, Naples
New York	Mount Sinai, New York
Texas	Baylor Heart Hospital Of Plano, Plano

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.